期刊
CELL
卷 183, 期 6, 页码 1508-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2020.10.052
关键词
-
资金
- SAMANA Kay MGH Research Scholarship
- Ragon Institute of MGH, MIT
- Massachusetts Consortium on Pathogen Readiness (MassCPR)
- NIAID [U01CA260476, U19 AI35995, R37AI80289, R01AI146785]
- U.S. Centers for Disease Control and Prevention [CK000490]
- NATIONAL CANCER INSTITUTE [U01CA260476] Funding Source: NIH RePORTER
The urgent need for an effective SARS-CoV-2 vaccine has forced development to progress in the absence of well-defined correlates of immunity. While neutralization has been linked to protection against other pathogens, whether neutralization alone will be sufficient to drive protection against SARS-CoV-2 in the broader population remains unclear Therefore, to fully define protective humoral immunity, we dissected the early evolution of the humoral response in 193 hospitalized individuals ranging from moderate to severe. Although robust IgM and IgA responses evolved in both survivors and non-survivors with severe disease, non-survivors showed attenuated IgG responses, accompanied by compromised Fcv receptor binding and Fc effector activity, pointing to deficient humoral development rather than disease-enhancing humoral immunity. In contrast, individuals with moderate disease exhibited delayed responses that ultimately matured. These data highlight distinct humoral trajectories associated with resolution of SARS-CoV-2 infection and the need for early functional humoral immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据